The purpose of the proposed research is to develop new approaches for designing compounds to treat neurological disorders. Changes in cholinergic activity have been implicated in a variety of pathological conditions including Alzheimer's disease and schizophrenia. Muscarinic agonists might be helpful in restoring the chemical imbalances in cholinergic activity associated with neurological disorders. Unfortunately, the development of new therapies is hindered by the propensity for muscarinic agonists to produce unwanted side effects due to activation of multiple receptor subtypes. An integrated approach to drug development is proposed whereby information from molecular biological and computational chemical studies is used in the design and development of selective muscarinic agonists. Chimeric receptors will be generated to help determine where molecules bind to muscarinic receptor subtypes. Molecular models of muscarinic receptors will be created in order to understand how agonists stabilize the active form of the receptor. Existing ligands will be docked into the muscarinic receptor model to verify interactions discovered in studies of chimeric receptors and to identify amino acid residues that represent binding sites for functional groups on selective ligands. New compounds will be designed and synthesized to take advantage of the information derived from the molecular biological and computational chemical studies. Compounds will be characterized for receptor binding properties and functional activities in cell lines expressing muscarinic receptor subtypes. Muscarinic agonists that display high activity and selectivity will be examined further in functional assays for enhancement of memory function and antipsychotic activity in animal models of Alzheimer's disease and schizophrenia, respectively. The studies outlined here will provide new approaches for the treatment of neurological disorders, including Alzheimer's disease and schizophrenia.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS031173-09
Application #
6895255
Study Section
Molecular Neuropharmacology and Signaling Study Section (MNPS)
Program Officer
Refolo, Lorenzo
Project Start
1994-08-08
Project End
2008-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
9
Fiscal Year
2005
Total Cost
$229,863
Indirect Cost
Name
University of Toledo
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
051623734
City
Toledo
State
OH
Country
United States
Zip Code
43606
Nagy, Peter I; Messer, William S (2011) Theoretical studies of the in-solution isomeric protonation of non-aromatic six-member rings with two nitrogens. J Phys Chem B 115:4758-67
Dokas, Linda A; Malone, Amy M; Williams, Frederick E et al. (2011) Multiple protein kinases determine the phosphorylated state of the small heat shock protein, HSP27, in SH-SY5Y neuroblastoma cells. Neuropharmacology 61:12-24
Nagy, Peter I; Maheshwari, Aditya; Kim, Yong-Wah et al. (2010) Theoretical and experimental studies of the isomeric protonation in solution for a prototype aliphatic ring containing two nitrogens. J Phys Chem B 114:349-60
Tejada, Frederick R; Nagy, Peter I; Xu, Min et al. (2006) Design and synthesis of novel derivatives of the muscarinic agonist tetra(ethylene glycol)(3-methoxy-1,2,5-thiadiazol-4-yl) [3-(1-methyl-1,2,5,6-tetrahydropyrid-3-yl)-1,2,5-thiadiazol-4-yl] ether (CDD-0304): effects of structural modifications on the bind J Med Chem 49:7518-31
Nagy, Peter I; Tejada, Frederick R; Messer Jr, William S (2005) Theoretical studies of the tautomeric equilibria for five-member N-heterocycles in the gas phase and in solution. J Phys Chem B 109:22588-602
Cao, Yang; Zhang, Minjia; Wu, Cindy et al. (2003) Synthesis and biological characterization of 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as muscarinic agonists for the treatment of neurological disorders. J Med Chem 46:4273-86
Messer Jr, William S (2002) The utility of muscarinic agonists in the treatment of Alzheimer's disease. J Mol Neurosci 19:187-93
Rajeswaran, W G; Cao, Y; Huang, X P et al. (2001) Design, synthesis, and biological characterization of bivalent 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as selective muscarinic agonists. J Med Chem 44:4563-76
Messer Jr, W S; Rajeswaran, W G; Cao, Y et al. (2000) Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors. Pharm Acta Helv 74:135-40
Huang, X P; Williams, F E; Peseckis, S M et al. (1999) Differential modulation of agonist potency and receptor coupling by mutations of Ser388Tyr and Thr389Pro at the junction of transmembrane domain VI and the third extracellular loop of human M(1) muscarinic acetylcholine receptors. Mol Pharmacol 56:775-83

Showing the most recent 10 out of 13 publications